

CDKN2A RABBIT PAB

货号: S220453

产品全名: CDKN2A 兔多抗

基因符号: ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A

UNIPROT ID: P42771 (Gene Accession - NP_000068)

背景: This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53.

抗原: Synthetic peptide of human CDKN2A

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 1000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling, Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human gastric cancer tissue using 220453(CDKN2A Antibody) at a dilution of 1/50(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human gastric cancer tissue is first treated with the synthetic peptide and then with 220453(Anti-CDKN2A Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using 220453(Anti-CDKN2A Antibody) at a dilution of 1/50.



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with synthetic peptide and then with D261550(Anti-CDKN2A Antibody) at dilution 1/50.